bluebird bio, Inc. (BLUE)
USD 4.8
(-1.84%)
USD 4.8
(-1.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 619.16 Million USD | 11.58% |
| 2022 | 554.9 Million USD | -6.55% |
| 2021 | 593.79 Million USD | -66.66% |
| 2020 | 1.78 Billion USD | 3.12% |
| 2019 | 1.72 Billion USD | -22.98% |
| 2018 | 2.24 Billion USD | 18.01% |
| 2017 | 1.9 Billion USD | 69.98% |
| 2016 | 1.11 Billion USD | 11.55% |
| 2015 | 1 Billion USD | 80.04% |
| 2014 | 556.73 Million USD | 148.11% |
| 2013 | 224.39 Million USD | 223.69% |
| 2012 | 69.32 Million USD | 124.21% |
| 2011 | 30.91 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 631.48 Million USD | 1.99% |
| 2024 Q2 | 545.19 Million USD | -13.66% |
| 2023 Q4 | 619.16 Million USD | 0.9% |
| 2023 FY | 619.16 Million USD | 11.58% |
| 2023 Q3 | 613.6 Million USD | -7.5% |
| 2023 Q1 | 692.73 Million USD | 24.84% |
| 2023 Q2 | 663.39 Million USD | -4.24% |
| 2022 FY | 554.9 Million USD | -6.55% |
| 2022 Q4 | 554.9 Million USD | 6.69% |
| 2022 Q1 | 491.07 Million USD | -17.3% |
| 2022 Q3 | 520.09 Million USD | -9.33% |
| 2022 Q2 | 573.59 Million USD | 16.8% |
| 2021 FY | 593.79 Million USD | -66.66% |
| 2021 Q1 | 1.63 Billion USD | -8.08% |
| 2021 Q2 | 1.45 Billion USD | -11.17% |
| 2021 Q3 | 1.33 Billion USD | -7.89% |
| 2021 Q4 | 593.79 Million USD | -55.68% |
| 2020 Q3 | 1.94 Billion USD | -7.7% |
| 2020 Q2 | 2.1 Billion USD | 37.84% |
| 2020 Q1 | 1.52 Billion USD | -11.48% |
| 2020 Q4 | 1.78 Billion USD | -8.44% |
| 2020 FY | 1.78 Billion USD | 3.12% |
| 2019 Q2 | 2.02 Billion USD | -5.39% |
| 2019 Q1 | 2.13 Billion USD | -4.65% |
| 2019 Q3 | 1.89 Billion USD | -6.48% |
| 2019 FY | 1.72 Billion USD | -22.98% |
| 2019 Q4 | 1.72 Billion USD | -8.71% |
| 2018 Q3 | 2.35 Billion USD | 33.51% |
| 2018 Q4 | 2.24 Billion USD | -4.63% |
| 2018 Q2 | 1.76 Billion USD | -5.64% |
| 2018 Q1 | 1.86 Billion USD | -1.78% |
| 2018 FY | 2.24 Billion USD | 18.01% |
| 2017 Q2 | 1.45 Billion USD | 35.85% |
| 2017 FY | 1.9 Billion USD | 69.98% |
| 2017 Q3 | 1.4 Billion USD | -3.53% |
| 2017 Q4 | 1.9 Billion USD | 35.2% |
| 2017 Q1 | 1.07 Billion USD | -4.07% |
| 2016 Q4 | 1.11 Billion USD | 21.77% |
| 2016 FY | 1.11 Billion USD | 11.55% |
| 2016 Q3 | 918.26 Million USD | -2.49% |
| 2016 Q2 | 941.66 Million USD | -3.78% |
| 2016 Q1 | 978.7 Million USD | -2.36% |
| 2015 Q2 | 999.16 Million USD | 87.17% |
| 2015 Q1 | 533.81 Million USD | -4.12% |
| 2015 FY | 1 Billion USD | 80.04% |
| 2015 Q4 | 1 Billion USD | -1.5% |
| 2015 Q3 | 1.01 Billion USD | 1.85% |
| 2014 Q4 | 556.73 Million USD | 68.61% |
| 2014 Q3 | 330.19 Million USD | 37.22% |
| 2014 Q1 | 209.51 Million USD | -6.63% |
| 2014 Q2 | 240.62 Million USD | 14.85% |
| 2014 FY | 556.73 Million USD | 148.11% |
| 2013 Q2 | 234.54 Million USD | 70.63% |
| 2013 Q3 | 228.26 Million USD | -2.68% |
| 2013 Q4 | 224.39 Million USD | -1.7% |
| 2013 FY | 224.39 Million USD | 223.69% |
| 2013 Q1 | 137.45 Million USD | 98.29% |
| 2012 Q4 | 69.32 Million USD | 0.0% |
| 2012 FY | 69.32 Million USD | 124.21% |
| 2011 FY | 30.91 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 58.392% |
| Alkermes plc | 2.13 Billion USD | 71.016% |
| Agenus Inc. | 313.91 Million USD | -97.24% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 83.833% |
| Aptorum Group Limited | 20.64 Million USD | -2899.798% |
| Ardelyx, Inc. | 297.57 Million USD | -108.066% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 19.122% |
| Bicycle Therapeutics plc | 595.34 Million USD | -4.001% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -740.087% |
| ChromaDex Corporation | 54.96 Million USD | -1026.485% |
| Chimerix, Inc. | 212.77 Million USD | -190.995% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2089.984% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -40.41% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 72.23% |
| Precision BioSciences, Inc. | 159.78 Million USD | -287.506% |
| Dyadic International, Inc. | 8.21 Million USD | -7433.072% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1850.728% |
| Fortress Biotech, Inc. | 167.52 Million USD | -269.591% |
| Lantern Pharma Inc. | 43.64 Million USD | -1318.545% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -283.769% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -4168.119% |
| Incyte Corporation | 6.78 Billion USD | 90.871% |
| IO Biotech, Inc. | 150.71 Million USD | -310.808% |
| Jaguar Health, Inc. | 50.76 Million USD | -1119.709% |
| Novavax, Inc. | 1.85 Billion USD | 66.628% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -62.763% |
| Opthea Limited | 188.79 Million USD | -227.961% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 25.677% |
| ContextLogic Inc. | 423 Million USD | -46.374% |
| MiMedx Group, Inc. | 239.04 Million USD | -159.012% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -256.401% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -11876.727% |
| NextCure, Inc. | 129.41 Million USD | -378.42% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1047.7% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1585.755% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1816.848% |
| Vaxcyte, Inc. | 1.4 Billion USD | 56.023% |
| PDS Biotechnology Corporation | 59.39 Million USD | -942.533% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 3.339% |
| Pharming Group N.V. | 462.85 Million USD | -33.77% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1500.726% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 1.495% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3171.886% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3171.886% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -274.523% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1267.194% |
| Acelyrin, Inc. | 742.69 Million USD | 16.633% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -9300.423% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -9569.858% |
| Summit Therapeutics Inc. | 202.94 Million USD | -205.082% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -732.497% |
| Senti Biosciences, Inc. | 119.48 Million USD | -418.196% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -171.155% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -268.167% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -7393.174% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -12870.069% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -31.963% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -400.725% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -125.191% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -30.945% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -6027.274% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -188.645% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -54588.52% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -49.613% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3007.433% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -67.33% |
| MEI Pharma, Inc. | 41.37 Million USD | -1396.462% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1810.637% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -81.68% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -428.182% |
| Fortress Biotech, Inc. | 167.52 Million USD | -269.591% |
| Precigen, Inc. | 151.04 Million USD | -309.924% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1720.098% |
| AlloVir, Inc. | 190.79 Million USD | -224.515% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -64.473% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -22.311% |
| ImmuCell Corporation | 43.8 Million USD | -1313.348% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 4.644% |
| Onconetix, Inc. | 88.82 Million USD | -597.085% |
| PureTech Health plc | 693.97 Million USD | 10.78% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -533.834% |
| Elevation Oncology, Inc. | 89.09 Million USD | -594.976% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -9883.247% |
| Seer, Inc. | 436.26 Million USD | -41.922% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -658.804% |
| Innoviva, Inc. | 1.24 Billion USD | 50.208% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -367.563% |
| ESSA Pharma Inc. | 149.12 Million USD | -315.204% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1266.304% |
| GT Biopharma, Inc. | 14.1 Million USD | -4288.412% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -101.096% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -156.166% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -31.204% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1121.297% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -550.297% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -97932.42% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -9.327% |
| Aptose Biosciences Inc. | 12.92 Million USD | -4691.324% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2699.824% |
| Soligenix, Inc. | 9.79 Million USD | -6219.694% |
| Century Therapeutics, Inc. | 360.69 Million USD | -71.66% |
| Kura Oncology, Inc. | 448.93 Million USD | -37.918% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -127.508% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -3480.0% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -458.249% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -201.807% |
| Autolus Therapeutics plc | 375.38 Million USD | -64.942% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -146.054% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -74.321% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1160.199% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 6.349% |
| GRI Bio, Inc. | 2.95 Million USD | -20845.907% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -5738.263% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -263.112% |
| IGM Biosciences, Inc. | 423.41 Million USD | -46.232% |
| INmune Bio, Inc. | 57 Million USD | -986.228% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -178.267% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -637.612% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2270.733% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -8895.256% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -723.068% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -320.46% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -274.106% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 1.659% |
| Verastem, Inc. | 149.71 Million USD | -313.551% |
| Abeona Therapeutics Inc. | 64 Million USD | -867.409% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -20.894% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -300.863% |
| Histogen Inc. | 19.07 Million USD | -3146.27% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -2633.582% |
| Surrozen, Inc. | 46.08 Million USD | -1243.665% |
| Organovo Holdings, Inc. | 6.34 Million USD | -9652.103% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -14270.286% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -329.893% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -5146.238% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -722.609% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -7167.788% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -70.582% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -3321.838% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -44.191% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -4809.41% |
| Apollomics, Inc. | 55.38 Million USD | -1017.881% |
| Amarin Corporation plc | 831.68 Million USD | 25.553% |
| Mesoblast Limited | 669.15 Million USD | 7.471% |
| Turnstone Biologics Corp. | 112.81 Million USD | -448.829% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -7.538% |
| Synaptogenix, Inc. | 31.11 Million USD | -1889.997% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -4981.755% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -12.973% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -10443.826% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -8329.511% |
| Exelixis, Inc. | 2.94 Billion USD | 78.957% |
| Better Therapeutics, Inc. | 22.94 Million USD | -2598.692% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -69.848% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 21.499% |
| NLS Pharmaceutics AG | 1.84 Million USD | -33429.04% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -7660.238% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -4113.413% |
| Gritstone bio, Inc. | 177.76 Million USD | -248.295% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -549.152% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -3366.306% |
| Avid Bioservices, Inc. | 336.55 Million USD | -83.969% |
| Insmed Incorporated | 1.32 Billion USD | 53.441% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -6330.607% |
| MediWound Ltd. | 66.45 Million USD | -831.644% |
| OmniAb, Inc. | 401.98 Million USD | -54.026% |
| Alector, Inc. | 621.82 Million USD | 0.429% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -72.661% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -11412.849% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -992.149% |
| Zai Lab Limited | 1.03 Billion USD | 40.252% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -29.409% |
| Aura Biosciences, Inc. | 255.07 Million USD | -142.737% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 17.448% |
| Immunic, Inc. | 54.29 Million USD | -1040.281% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -132.571% |
| Veracyte, Inc. | 1.13 Billion USD | 45.584% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -5137.016% |
| FibroGen, Inc. | 423.52 Million USD | -46.191% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -17524.851% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -12971.831% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -11303.693% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 94.566% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -6931.925% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -19.655% |
| TG Therapeutics, Inc. | 329.58 Million USD | -87.86% |
| Galecto, Inc. | 38.22 Million USD | -1519.696% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2059.161% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 85.79% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -163.021% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2392.396% |
| XBiotech Inc. | 227.24 Million USD | -172.466% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -549.152% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -334.194% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -116.553% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -384.215% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -62.084% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 58.474% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -69.707% |
| Vaxxinity, Inc. | 44.35 Million USD | -1295.984% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -19.77% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -3227.153% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -102.97% |
| NexImmune, Inc. | 8.59 Million USD | -7104.616% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -5678.348% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -3515.034% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.128% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2695.167% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -157742.53% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -257.217% |
| Ainos, Inc. | 31.84 Million USD | -1844.491% |
| Pluri Inc. | 39.52 Million USD | -1466.425% |
| Prothena Corporation plc | 696.38 Million USD | 11.089% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -119.082% |
| Celularity Inc. | 143.88 Million USD | -330.305% |
| Rallybio Corporation | 115.62 Million USD | -435.514% |
| Cue Biopharma, Inc. | 61.53 Million USD | -906.275% |
| MeiraGTx Holdings plc | 458.16 Million USD | -35.138% |
| Omeros Corporation | 378.26 Million USD | -63.683% |
| Humacyte, Inc. | 128.22 Million USD | -382.878% |
| Immunocore Holdings plc | 597 Million USD | -3.712% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1880.745% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -803.489% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 40.99% |
| CalciMedica, Inc. | 12.18 Million USD | -4981.338% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -144.101% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -262.277% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -99.065% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -9.528% |
| Pulmatrix, Inc. | 33.95 Million USD | -1723.314% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2180.855% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -339.564% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 52.408% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -375.586% |
| Cytokinetics, Incorporated | 824.31 Million USD | 24.888% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2831.217% |
| Nutriband Inc. | 7.51 Million USD | -8136.641% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -684.205% |
| Vor Biopharma Inc. | 209.82 Million USD | -195.08% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 91.427% |
| Evogene Ltd. | 51.1 Million USD | -1111.642% |
| ProKidney Corp. | 420.55 Million USD | -47.226% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1029.176% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -6403.602% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -13.321% |
| CorMedix Inc. | 82.05 Million USD | -654.523% |
| BioLineRx Ltd. | 63.92 Million USD | -868.574% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -53.803% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2095.606% |
| Atai Life Sciences N.V. | 293.47 Million USD | -110.974% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -279.552% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -385.929% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -10.166% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -540.165% |
| MediciNova, Inc. | 66.26 Million USD | -834.301% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -604.008% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -13775.176% |
| GeoVax Labs, Inc. | 9.28 Million USD | -6569.68% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -5.257% |
| Biomea Fusion, Inc. | 199.92 Million USD | -209.694% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 67.467% |
| Mereo BioPharma Group plc | 66.49 Million USD | -831.083% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -27.637% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -1.025% |
| Absci Corporation | 234.48 Million USD | -164.057% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -8364.265% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -82.165% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -275.063% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -17.639% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -122.966% |
| Allakos Inc. | 243.61 Million USD | -154.161% |
| Imunon, Inc. | 21.91 Million USD | -2724.888% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -140.27% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 0.379% |
| BioAtla, Inc. | 119.65 Million USD | -417.442% |
| NLS Pharmaceutics AG | 1.84 Million USD | -33429.04% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -19128.602% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 3.683% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -545.396% |
| XOMA Corporation | 234.3 Million USD | -164.259% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -179.866% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -392.007% |
| aTyr Pharma, Inc. | 122.06 Million USD | -407.23% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -302.306% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -6.702% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -26.25% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -460.484% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -3984.833% |
| Akari Therapeutics, Plc | 4.35 Million USD | -14117.245% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3534.143% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 64.278% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -19976.648% |
| UroGen Pharma Ltd. | 178.31 Million USD | -247.237% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -31.53% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -111317.003% |
| Orgenesis Inc. | 14.55 Million USD | -4154.817% |
| Entera Bio Ltd. | 11.76 Million USD | -5162.737% |
| GH Research PLC | 226.3 Million USD | -173.602% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1032.046% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -476.307% |
| Xencor, Inc. | 952.69 Million USD | 35.009% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -7854.512% |
| Replimune Group, Inc. | 487.72 Million USD | -26.95% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -7571.344% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 4.515% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -19976.648% |
| Portage Biotech Inc. | 7.77 Million USD | -7859.391% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -13775.176% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -123.568% |
| OncoCyte Corporation | 74.89 Million USD | -726.739% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -30351.819% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -10599.831% |
| Purple Biotech Ltd. | 44.3 Million USD | -1297.592% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1714.338% |
| scPharmaceuticals Inc. | 94.47 Million USD | -555.342% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -3331.213% |
| HilleVax, Inc. | 344.43 Million USD | -79.762% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -19394.994% |
| Tharimmune, Inc. | 10.94 Million USD | -5556.302% |
| Genprex, Inc. | 10.67 Million USD | -5702.499% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -24.782% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -543.271% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -25421.888% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -14764.236% |
| OKYO Pharma Limited | 1.54 Million USD | -40072.287% |
| Savara Inc. | 177.56 Million USD | -248.697% |
| Curis, Inc. | 77.28 Million USD | -701.171% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2809.288% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -868.214% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -7557.198% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3096.33% |
| BeiGene, Ltd. | 5.8 Billion USD | 89.335% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -4988.019% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 70.355% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -72.974% |
| Erasca, Inc. | 395.29 Million USD | -56.632% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -14221.262% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 90.95% |
| DBV Technologies S.A. | 182.98 Million USD | -238.365% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -14221.262% |
| Moderna, Inc. | 18.42 Billion USD | 96.64% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -3298.809% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -5244.045% |
| Molecular Templates, Inc. | 35.38 Million USD | -1649.883% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -347.807% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 21.517% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -103.836% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -495.656% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -32.974% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -97.539% |
| MacroGenics, Inc. | 306.82 Million USD | -101.799% |
| RenovoRx, Inc. | 1.46 Million USD | -42134.72% |
| Adicet Bio, Inc. | 207.29 Million USD | -198.686% |
| Prime Medicine, Inc. | 193.85 Million USD | -219.4% |
| Aditxt, Inc. | 44.57 Million USD | -1288.928% |
| Adagene Inc. | 115.72 Million USD | -435.01% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -13800.645% |
| Quantum-Si incorporated | 298.25 Million USD | -107.598% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 58.374% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -7931.536% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -76.258% |
| SciSparc Ltd. | 11.18 Million USD | -5437.122% |
| Vericel Corporation | 353.65 Million USD | -75.074% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -4969.85% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -988.145% |
| Generation Bio Co. | 374.75 Million USD | -65.216% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -143.127% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -290.473% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -81.378% |
| Invivyd, Inc. | 229.18 Million USD | -170.162% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 26.638% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -4987.893% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -239.471% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2931.536% |
| 2seventy bio, Inc. | 565.42 Million USD | -9.503% |
| ADMA Biologics, Inc. | 329.18 Million USD | -88.091% |
| Clene Inc. | 52.34 Million USD | -1082.937% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -954.172% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -376.666% |
| GeoVax Labs, Inc. | 9.28 Million USD | -6569.68% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 5.283% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -497.581% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -374.868% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -534.698% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -772.095% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -155.268% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 68.412% |
| Evaxion Biotech A/S | 12.88 Million USD | -4703.936% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -145.64% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 17.74% |
| Trevena, Inc. | 40.6 Million USD | -1424.839% |
| Surrozen, Inc. | 46.08 Million USD | -1243.665% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -174.139% |
| Cingulate Inc. | 3.49 Million USD | -17633.706% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -3623.381% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -842.55% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -5198.937% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -130.585% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 17.33% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -391.819% |
| Clearmind Medicine Inc. | 4.32 Million USD | -14217.884% |
| Kronos Bio, Inc. | 213.27 Million USD | -190.306% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -287.499% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -7132.674% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -68.027% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2824.753% |
| ImmunityBio, Inc. | 504.45 Million USD | -22.739% |
| Korro Bio, Inc. | 221.66 Million USD | -179.325% |
| Kineta, Inc. | 10.28 Million USD | -5922.381% |
| BioVie Inc. | 25.2 Million USD | -2356.175% |
| Codexis, Inc. | 136.56 Million USD | -353.395% |
| Celularity Inc. | 143.88 Million USD | -330.305% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 2.549% |
| Celcuity Inc. | 191.21 Million USD | -223.796% |
| Virax Biolabs Group Limited | 5.48 Million USD | -11190.381% |
| Cibus, Inc. | 544.41 Million USD | -13.73% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -391.811% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2913.829% |
| IN8bio, Inc. | 33.7 Million USD | -1736.782% |
| Kodiak Sciences Inc. | 479.37 Million USD | -29.161% |
| Annexon, Inc. | 297.67 Million USD | -108.0% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -257.876% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -350.4% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2849.369% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 79.293% |
| Eyenovia, Inc. | 28.77 Million USD | -2051.405% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -168.584% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -8470.889% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -916.251% |
| Arcellx, Inc. | 825.13 Million USD | 24.962% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -658.432% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -33.938% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1913.532% |
| Moolec Science SA | 24.05 Million USD | -2474.336% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -99.649% |
| Geron Corporation | 394.07 Million USD | -57.117% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -508.751% |
| Royalty Pharma plc | 16.38 Billion USD | 96.22% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -4.066% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -8751.714% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -5047.957% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -173.892% |
| Humacyte, Inc. | 128.22 Million USD | -382.878% |
| Structure Therapeutics Inc. | 482.01 Million USD | -28.452% |
| 89bio, Inc. | 596.26 Million USD | -3.839% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -145.551% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -33368.162% |
| Genelux Corporation | 27.89 Million USD | -2119.772% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -592.551% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -169.87% |
| Notable Labs, Ltd. | 19.54 Million USD | -3068.523% |
| Liquidia Corporation | 120.43 Million USD | -414.121% |
| Mustang Bio, Inc. | 17.74 Million USD | -3389.804% |
| Immunovant, Inc. | 666.71 Million USD | 7.132% |
| Quantum-Si incorporated | 298.25 Million USD | -107.598% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -328.779% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1043.207% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -252.706% |
| Acasti Pharma Inc. | 73.3 Million USD | -744.694% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -13501.116% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2270.733% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 35.825% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -11830.073% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -2617.883% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1099.855% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -242.663% |
| PepGen Inc. | 143.05 Million USD | -332.822% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1520.119% |
| United Therapeutics Corporation | 7.16 Billion USD | 91.361% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3127.318% |
| Solid Biosciences Inc. | 164.93 Million USD | -275.388% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -10443.826% |
| Immuneering Corporation | 102.58 Million USD | -503.562% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -14270.286% |
| Silo Pharma, Inc. | 7.74 Million USD | -7893.154% |
| Belite Bio, Inc | 94.64 Million USD | -554.214% |
| XOMA Corporation | 234.3 Million USD | -164.259% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -165.52% |
| Bionomics Limited | 27.64 Million USD | -2139.354% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -54.249% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -476.564% |
| uniQure N.V. | 831.68 Million USD | 25.554% |
| Cassava Sciences, Inc. | 151.66 Million USD | -308.248% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -13800.645% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -126.066% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1488.407% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -15101.17% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1581.087% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -8470.889% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -17524.851% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -5137.806% |
| Altimmune, Inc. | 210.64 Million USD | -193.943% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 20.404% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -476.564% |
| Compugen Ltd. | 121.33 Million USD | -410.295% |
| Peak Bio, Inc. | 2.59 Million USD | -23746.766% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -259.294% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1085.905% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -81.116% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1680.58% |
| Zura Bio Limited | 100.84 Million USD | -513.985% |
| PolyPid Ltd. | 15.37 Million USD | -3927.849% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -419.056% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1680.58% |
| Instil Bio, Inc. | 325.63 Million USD | -90.142% |
| argenx SE | 4.54 Billion USD | 86.369% |
| Immunome, Inc. | 148.54 Million USD | -316.831% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -294.684% |
| Verona Pharma plc | 308.12 Million USD | -100.945% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -612.015% |
| Shattuck Labs, Inc. | 159.56 Million USD | -288.033% |
| CervoMed Inc. | 9.97 Million USD | -6108.671% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -228.544% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -5336.96% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -245.119% |
| Moolec Science SA | 24.05 Million USD | -2474.336% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -10021.177% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -258.012% |
| AnaptysBio, Inc. | 452.38 Million USD | -36.865% |
| Design Therapeutics, Inc. | 289.64 Million USD | -113.767% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -750.204% |
| NeurAxis, Inc. | 509.49 Thousand USD | -121423.735% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -11327.852% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1423.601% |
| Achilles Therapeutics plc | 161.45 Million USD | -283.486% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -612.015% |
| 180 Life Sciences Corp. | 5.25 Million USD | -11672.294% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -779.143% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -7132.674% |
| Nutriband Inc. | 7.51 Million USD | -8136.641% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -143.108% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -210.666% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -712.419% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -969.067% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -17.59% |
| Palisade Bio, Inc. | 14.05 Million USD | -4306.213% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -194.425% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 57.583% |
| Neurogene Inc. | 222.57 Million USD | -178.183% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 4.247% |
| AEON Biopharma, Inc. | 6.84 Million USD | -8945.449% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -36.669% |
| Sesen Bio, Inc. | 189.17 Million USD | -227.297% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -127.744% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -4415.511% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 20.656% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -131.901% |
| Athira Pharma, Inc. | 160.24 Million USD | -286.384% |
| Vaccinex, Inc. | 3.63 Million USD | -16952.079% |
| HCW Biologics Inc. | 28.51 Million USD | -2071.454% |
| XOMA Corporation | 234.3 Million USD | -164.259% |
| Nektar Therapeutics | 398.03 Million USD | -55.555% |
| Arvinas, Inc. | 1.3 Billion USD | 52.54% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3534.143% |
| Merus N.V. | 458.49 Million USD | -35.042% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -202.967% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -243.589% |
| Rezolute, Inc. | 132.73 Million USD | -366.457% |
| Clene Inc. | 52.34 Million USD | -1082.937% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -4048.794% |
| BeyondSpring Inc. | 24.8 Million USD | -2395.812% |
| Synlogic, Inc. | 75.55 Million USD | -719.538% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -5119.702% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -6512.142% |
| Peak Bio, Inc. | 2.59 Million USD | -23746.766% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -254.144% |
| Krystal Biotech, Inc. | 818.35 Million USD | 24.341% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -157.514% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 14.691% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -17208.663% |
| MannKind Corporation | 475.19 Million USD | -30.295% |
| Ikena Oncology, Inc. | 192.09 Million USD | -222.325% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -4529.587% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -431.291% |
| Gossamer Bio, Inc. | 311.91 Million USD | -98.502% |
| CohBar, Inc. | 16.36 Million USD | -3683.292% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1660.831% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -8364.265% |
| Legend Biotech Corporation | 1.84 Billion USD | 66.507% |
| Mural Oncology plc | 301.74 Million USD | -105.193% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1883.537% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -10799.945% |
| Disc Medicine, Inc. | 367.99 Million USD | -68.252% |
| Champions Oncology, Inc. | 26.13 Million USD | -2269.359% |
| REGENXBIO Inc. | 573.97 Million USD | -7.873% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -22763.426% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -301.047% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -5027.381% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -82.087% |
| Vaxart, Inc. | 91.83 Million USD | -574.247% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -933.591% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -317.43% |
| Cellectis S.A. | 334.27 Million USD | -85.228% |
| Longeveron Inc. | 12.17 Million USD | -4984.258% |
| Repare Therapeutics Inc. | 253.9 Million USD | -143.859% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 81.034% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -208.275% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 70.355% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -38002.215% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -122.952% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -279.625% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -346.261% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2325.989% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.276% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 46.343% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -4969.85% |
| Veru Inc. | 50.59 Million USD | -1123.737% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1259.21% |
| Cingulate Inc. | 3.49 Million USD | -17633.706% |
| Passage Bio, Inc. | 150.54 Million USD | -311.28% |
| Context Therapeutics Inc. | 16.06 Million USD | -3754.642% |
| Exicure, Inc. | 11.58 Million USD | -5246.813% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -64.649% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -283.045% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -3443.733% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -86.077% |
| Nuvalent, Inc. | 732.38 Million USD | 15.46% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -4043.186% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -591.383% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -4263.054% |
| OmniAb, Inc. | 401.98 Million USD | -54.026% |
| Anew Medical, Inc. | 19.45 Million USD | -3082.373% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2216.651% |
| Lipocine Inc. | 23 Million USD | -2591.879% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -342.868% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -102.628% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -637.612% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -409.43% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -7702.911% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 29.822% |
| Ocugen, Inc. | 64.54 Million USD | -859.241% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -397.154% |
| Q32 Bio Inc. | 306.11 Million USD | -102.262% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -14613.902% |
| Alumis Inc. Common Stock | 89.61 Million USD | -590.935% |
| Equillium, Inc. | 50.53 Million USD | -1125.333% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -723.407% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1400.141% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -36302.97% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2268.544% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -860.818% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -16512.348% |
| Dominari Holdings Inc. | 57.55 Million USD | -975.717% |
| Edesa Biotech, Inc. | 8.89 Million USD | -6864.348% |
| vTv Therapeutics Inc. | 11.01 Million USD | -5519.541% |
| Bio-Techne Corporation | 2.81 Billion USD | 77.991% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 33.929% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 23.697% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -122.988% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1384.727% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 7.254% |
| Nkarta, Inc. | 378.88 Million USD | -63.417% |
| BioCardia, Inc. | 2.98 Million USD | -20628.524% |
| Iterum Therapeutics plc | 26.25 Million USD | -2257.9% |